NET Patient Day 2022 – Part 1 – Presentations
NET Patient Day 2022 – Part 1 – Presentations
NET Patient Day 2022 – Part 2 – Panel Q&A
St Vincents NET Centre of Excellence
RTE News Centre of Excellence 2017
Patient Day 2016 – A Patients Perspective
Patient Day 2016 – Q17 – Sandostatin injection clogs
Patient Day 2016 – Patient Comments & Wrap-up
Patient Day 2016 – Q18 – Ga-PET scan after tumour removal
Patient Day 2016 – Q16 – Insurance and injections/scans
Patient Day 2016 – Q15 – Somatostatins with no visible disease
Patient Day 2016 – Q14 – Access to proper care
Patient Day 2016 – Q13 – Diabetes and carcinoid
Patient Day 2016 – Q12 – Communications between SVUH and satellites
Patient Day 2016 – Q11 – Awareness of NETs System by medics
Patient Day 2016 – Q10 – Patient referrals and responsibilities
Patient Day 2016 – Q9 – PRRT and octreotide uptake
Patient Day 2016 – Q8 – Somatostatins prevent recurrence
Patient Day 2016 – Q7 – Lung NETs
Patient Day 2016 – Q6 – Overview of disease and treatments
Patient Day 2016 – Q5 – Tumour debulking treatment
Patient Day 2016 – Q4 – Pharmacist Representative
Patient Day 2016 – Q3 – Coconut oil supplement
Patient Day 2016 – Q2 – Weight control with Carcinoid Syndrome
Patient Day 2016 – Q1 – Update from Uppsala
Patient Day 2016 – Nutrition and NETs
Patient Day 2016 – Where Next?
Patient Day 2016 – Survivorship
Patient Day 2016 – Welcome Address
Patient Day 2016 – Opening Address
Patient Day 2015 – Q12 – Should mandatory referral of NETs be implemented?
Patient Day 2015 – Dr Derek Power
Patient Day 2015 – Q15 – Are MIBG and MCI treatments dosage limited?
Patient Day 2015 – Treatment Abroad
Patient Day 2015 – Q7 – What treatments are available for lung NETs?
Patient Day 2015 – Mindfullness
Patient Day 2015 – Q17 – Has patient experience improved with somatostatin injections?
Patient Day 2015 – Q13 – What is the latest info on the oncolytic virus?
Patient Day 2015 – Prof Barbro Eriksson
Patient Day 2015 – Q6 – Are there clinical trials for NETs?
Patient Day 2015 – Mr Criostoir OâSuilleabhain
Patient Day 2015 – Q16 – Is surgery always 1st choice treatment?
Patient Day 2015 – Q10 – Is Ki67 monitored and can it change?
Patient Day 2015 – Q9 – What regimen should MEN1/Paraganglioma patients follow?
Patient Day 2015 – Q2 – Can someone from outside Ireland be treated here?
Patient Day 2015 – Q1 – Can NETs be cured?
Patient Day 2015 – Q8 – How important is dosimetry for PRRT?
Patient Day 2015 – Q11 – Should NET patients attend a specialist NET centre?
Patient Day 2015 – Q14 – Can drugs treat bone metatases?
Patient Day 2015 – Q4 – How are southern region patients handled?
Patient Day 2015 – Prof Dermot O’Toole
Patient Day 2015 – Q5 – Are public and private patients treated equally?
Patient Day 2015 – Welcome Address
Patient Day 2015 – Q3 – What treatments are possible following PRRT and chemotherapy?
Patient Day 2014 – Diagnostics & Terminology
Patient Day 2014 – Q14 – PET Scanning in Ireland?
Patient Day 2014 – Q16 – Does somatostatin cause weight gain?
Patient Day 2016 – Survivorship
Patient Day 2016 – Welcome Address
Patient Day 2016 – Opening Address
Patient Day 2015 – Q12 – Should mandatory referral of NETs be implemented?
Patient Day 2015 – Dr Derek Power
Patient Day 2015 – Q15 – Are MIBG and MCI treatments dosage limited?
Patient Day 2015 – Treatment Abroad
Patient Day 2015 – Q7 – What treatments are available for lung NETs?
Patient Day 2015 – Mindfullness
Patient Day 2015 – Q17 – Has patient experience improved with somatostatin injections?
Patient Day 2015 – Q13 – What is the latest info on the oncolytic virus?
Patient Day 2015 – Prof Barbro Eriksson
Patient Day 2015 – Q6 – Are there clinical trials for NETs?
Patient Day 2015 – Mr Criostoir OâSuilleabhain
Patient Day 2015 – Q16 – Is surgery always 1st choice treatment?
Patient Day 2015 – Q10 – Is Ki67 monitored and can it change?
Patient Day 2015 – Q9 – What regimen should MEN1/Paraganglioma patients follow?
Patient Day 2015 – Q2 – Can someone from outside Ireland be treated here?
Patient Day 2015 – Q1 – Can NETs be cured?
Patient Day 2015 – Q8 – How important is dosimetry for PRRT?
Patient Day 2015 – Q11 – Should NET patients attend a specialist NET centre?
Patient Day 2015 – Q14 – Can drugs treat bone metatases?
Patient Day 2015 – Q4 – How are southern region patients handled?
Patient Day 2015 – Prof Dermot O’Toole
Patient Day 2015 – Q5 – Are public and private patients treated equally?
Patient Day 2015 – Welcome Address
Patient Day 2015 – Q3 – What treatments are possible following PRRT and chemotherapy?
Patient Day 2014 – Diagnostics & Terminology
Patient Day 2014 – Q14 – PET Scanning in Ireland?
Patient Day 2014 – Q16 – Does somatostatin cause weight gain?
Patient Day 2014 – Q15 – Is there a waiting list for PRRT in Sweden?
Patient Day 2014 – Q12 – Should I carry a NET ID card?
Patient Day 2014 – Q13 – Alternatives to Sandostatin LAR?
Patient Day 2014 – Q11 – Is NETs genetic?
Patient Day 2014 – Q9 – Expected outcomes after surgery?
Patient Day 2014 – Q10 – How often should I be scanned?
Patient Day 2014 – Q8 – Do NET treatments affect fertility?
Patient Day 2014 – Q7 – Do environment factors affect NETs?
Patient Day 2014 – Q6 – Does long-term use of somatostatin affect bones?
Patient Day 2014 – Q5 – Can I travel with somatostatin?
Patient Day 2014 – Q4 – Can you overdoes on somatostatin?
Patient Day 2014 – Q3 – When should kids be screened for MEN?
Patient Day 2014 – Q2 – How to advise A&E about NETs?
Patient Day 2014 – Q1 – Treatments for Bone Metastases?
Patient Day 2014 – Welcome Address
Patient Day 2014 – Opening Address
Patient Day 2014 – Treatment Abroad Discussion
Patient Day 2014 – Somatuline (Lanreotide) Injection Tips
Patient Day 2014 – Sandostatin LAR Injection Tips
Patient Day 2014 – Dr Dan Granberg (Uppsala)
Patient Day 2014 – Prof Dermot O’Toole (National Lead NETs)
Patient Day 2014 – Jermone Coffey NCCP
Q14 What improvements can we expect to see with the treatment of NET patients in Ireland?
Q17 Does somatostatin cause raised sugar and glucose levels?
Q16 What are the problems with weight maintenance due to NETs?
Q15 How effective is lanreotide in treating NETs?
Q13 Is there any connection between thyroid cancer and NETs?
Q12 What future treatments are coming down the line?
Q11 What impact does NET treatments have for patients with heart problems?
Q10 Is there any diet that can help to treat NETs?
Q9 Can an undetectable NET tumour cause Carcinoid Syndrome?
Q8 Can a slow-growing NET cancer change to become more aggressive?
Q7 Could heavy bleeding from a prostate biopsy be due to monthly sandostatin injections?
Q6 Should patients with Carcinoid Syndrome carry an “at risk” identifier?
Q5 What is the necessity for octreotide infusions prior to minor surgeries?
Q4 Should international NET experts be included in the Irish Centre of Excellence for NETs?
Q3 How effective is standard treatments vs NET treatments for breast cancer with NET properties?
Q2 Should a patient with high-grade NET be referred to a specialist NET centre?
Q1 Are we likely to have Lutetium treatment in Ireland?
NET Patient Day 2013 – Per Hellman
NET Patient Day 2013 – Bill Claxton
